Found: 6
Select item for more details and to access through your institution.
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD) study.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 5, p. 781, doi. 10.1111/bjh.19058
- By:
- Publication type:
- Article
BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 1, p. 136, doi. 10.1111/bjh.17807
- By:
- Publication type:
- Article
Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 4, p. 779, doi. 10.1111/bjh.17447
- By:
- Publication type:
- Article
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
- Published in:
- European Journal of Haematology, 2016, v. 97, n. 5, p. 471, doi. 10.1111/ejh.12757
- By:
- Publication type:
- Article
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
- Published in:
- 2015
- By:
- Publication type:
- journal article
An evaluation of no‐treatment decisions in patients with newly diagnosed acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 1, p. E17, doi. 10.1002/ajh.26012
- By:
- Publication type:
- Article